SRC and melanoma: First developed as an inhibitor for lysosomal acid ceramidase (Bielawska et al., 1996) to induce ceramide-provoked apoptosis as therapeutic strategy for melanoma (Raisova et al., 2002), 4 was recently claimed to influence c-Src activation through inhibition of NMT, at up to 30 μM 4 (Kim et al., 2017).